Hotspots of Anal Cancer Screening in a High-risk Population: A Clinical Study on Free Provision, Best Method, Self-sampling, and Independent Risk Factors.

IF 1.6 4区 医学 Q4 ONCOLOGY Anticancer research Pub Date : 2024-10-01 DOI:10.21873/anticanres.17276
Edoardo Virgilio, Carlo Salvemini, Maria Grazia Treglia, Elena Thai, Eva Franchi, Sara Panico, Luigi Ippolito, Clara Pavlidis, Alfredo Annicchiarico, Enrico Maria Silini, Renato Costi
{"title":"Hotspots of Anal Cancer Screening in a High-risk Population: A Clinical Study on Free Provision, Best Method, Self-sampling, and Independent Risk Factors.","authors":"Edoardo Virgilio, Carlo Salvemini, Maria Grazia Treglia, Elena Thai, Eva Franchi, Sara Panico, Luigi Ippolito, Clara Pavlidis, Alfredo Annicchiarico, Enrico Maria Silini, Renato Costi","doi":"10.21873/anticanres.17276","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>As of 2024, anal cancer (AC) has been steadily increasing worldwide but, due to insufficient evidence, anal cancer screening (ACS) has yet to be standardized. Furthermore, most high-risk people in the world have no help paying for it. Therefore, our primary endpoint was to assess the best screening method for these subjects through a provision that was free of charge (all costs were covered by the Italian public health service). Awareness-raising campaign, determination of risk factors, education on anal self-examination, and sampling (ASS) were secondary objectives.</p><p><strong>Patients and methods: </strong>Screening was on a voluntary basis. Engaging in receptive anal intercourse and having a history of cervical dysplasia were the main inclusion criteria. Level 1 ACS tools included digital ano-rectal examination, anoscopy, anal Pap, and anal human papillomavirus (HPV) DNA test (both through self- and proctologist- sampling); high-resolution anoscopy (HRA) with (HRAB) or without biopsy comprised level 2 screening. High-risk people were enrolled until the available funds were exhausted.</p><p><strong>Results: </strong>Fifty high-risk people (40 men who had sex with men -MSM-, 9 women, and 1 heterosexual man) were enrolled. AC was found in one HIV-seropositive MSM, high-grade squamous intraepithelial lesion in 10 (20%) MSM, low-grade squamous intraepithelial lesion LSIL in 13 cases (12 MSM and 1 woman). The combination of HRAB and Pap smear screening achieved the highest values for sensitivity, specificity, and accuracy. ASS HPV DNA test provided excellent results comparable to clinician retrieval. Overweight and college education were identified as independent factors for the risk of and prevention of AC, respectively.</p><p><strong>Conclusion: </strong>A free ACS not only appears justified but also recommended to people screened for AC. Excess weight represents a further risk for this population.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4465-4481"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17276","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: As of 2024, anal cancer (AC) has been steadily increasing worldwide but, due to insufficient evidence, anal cancer screening (ACS) has yet to be standardized. Furthermore, most high-risk people in the world have no help paying for it. Therefore, our primary endpoint was to assess the best screening method for these subjects through a provision that was free of charge (all costs were covered by the Italian public health service). Awareness-raising campaign, determination of risk factors, education on anal self-examination, and sampling (ASS) were secondary objectives.

Patients and methods: Screening was on a voluntary basis. Engaging in receptive anal intercourse and having a history of cervical dysplasia were the main inclusion criteria. Level 1 ACS tools included digital ano-rectal examination, anoscopy, anal Pap, and anal human papillomavirus (HPV) DNA test (both through self- and proctologist- sampling); high-resolution anoscopy (HRA) with (HRAB) or without biopsy comprised level 2 screening. High-risk people were enrolled until the available funds were exhausted.

Results: Fifty high-risk people (40 men who had sex with men -MSM-, 9 women, and 1 heterosexual man) were enrolled. AC was found in one HIV-seropositive MSM, high-grade squamous intraepithelial lesion in 10 (20%) MSM, low-grade squamous intraepithelial lesion LSIL in 13 cases (12 MSM and 1 woman). The combination of HRAB and Pap smear screening achieved the highest values for sensitivity, specificity, and accuracy. ASS HPV DNA test provided excellent results comparable to clinician retrieval. Overweight and college education were identified as independent factors for the risk of and prevention of AC, respectively.

Conclusion: A free ACS not only appears justified but also recommended to people screened for AC. Excess weight represents a further risk for this population.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高危人群中的肛门癌筛查热点:关于免费提供、最佳方法、自我采样和独立风险因素的临床研究。
背景/目的:截至 2024 年,肛门癌(AC)发病率在全球稳步上升,但由于证据不足,肛门癌筛查(ACS)尚未标准化。此外,世界上大多数高危人群都无力支付筛查费用。因此,我们的首要目标是通过免费提供(所有费用由意大利公共卫生服务机构承担)的方式,为这些受试者评估最佳筛查方法。提高认识运动、确定风险因素、肛门自检教育和取样(ASS)是次要目标:筛查以自愿为基础。主要纳入标准是有肛交史和宫颈发育不良史。一级 ACS 工具包括数字肛门直肠检查、肛门镜检查、肛门巴氏涂片和肛门人类乳头瘤病毒(HPV)DNA 检测(通过自我采样和直肠镜采样);二级筛查包括高分辨率肛门镜检查(HRA)和(HRAB)活检或不活检。在可用资金用完之前,高危人群一直在接受筛查:50 名高危人群(40 名男男性行为者、9 名女性和 1 名异性恋男性)接受了筛查。其中,1 名艾滋病毒血清反应呈阳性的 MSM 发现了 AC,10 名 MSM(20%)发现了高级别鳞状上皮内病变,13 例(12 名 MSM 和 1 名女性)发现了低级别鳞状上皮内病变 LSIL。HRAB和巴氏涂片筛查的组合在敏感性、特异性和准确性方面都达到了最高值。ASS HPV DNA 测试提供了与临床医生检索结果相当的优异结果。超重和大学教育程度分别被认为是导致 AC 风险和预防 AC 的独立因素:结论:免费的 ACS 似乎不仅合理,而且值得推荐给接受 AC 筛选的人。体重超标是这一人群面临的另一个风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Anticancer research
Anticancer research 医学-肿瘤学
CiteScore
3.70
自引率
10.00%
发文量
566
审稿时长
2 months
期刊介绍: ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
期刊最新文献
A Gene Expression Signature that Predicts Gastric Cancer Sensitivity to PARP Inhibitor Therapy. A Prospective Observational Study Analyzing the Diversity and Specific Composition of the Oral and Gut Microbiota in Lung Cancer Patients. Accuracy of Preoperative Magnet Resonance Imaging to Predict Pathologic T-Stage in Patients With Cervical Cancer. Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer. Association of Plasma Nestin With Response to Immune Checkpoint Inhibitors Combined With Chemotherapy in Extensive-stage Small-cell Lung Cancer: A Pilot Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1